Genomics may be the most recent drug discovery approach believed to represent a renewable source of therapeutic compounds, but the more conventional natural product approach has by no means been exhausted. In fact, Calyx Therapeutics Inc. believes it can find more than enough candidate compounds in botanical extracts with centuries of history as part of Ayurvedic medicine practices in India.

The company develops small molecule analogs of active ingredients from natural extracts that have shown clinical activity in humans. It has four lead compounds to treat diabetes, including CLX-0901, which is in Phase Ib testing, and two lead compounds to treat rheumatoid arthritis (RA) and other inflammatory disorders.